Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PPID | Q08752 | 2/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320541 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1143549 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27584197 | 0.93 | L3MBTL1 (0.65) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11659161 | 0.90 | CA2 (0.51) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8722042 | 0.90 | CA2 (0.50) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16509378 | 0.89 | L3MBTL1 (0.61) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31389164 | 0.88 | L3MBTL1 (0.58) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11631574 | 0.88 | L3MBTL1 (0.67) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11631569 | 0.88 | L3MBTL1 (0.67) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6308156 | 0.87 | L3MBTL1 (0.57) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11054430-B2 | Compounds and methods for the detection of methotrexate | DEFINED DIAGNOSTICS, LLC (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2017106426-A1 | FE NANOPARTICLES WITH PPM CONTENTS OF PD, CU AND/OR NI, REACTIONS IN WATER CATALYZED BY THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | LIPSHUTZ BRUCE H (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | LIPSHUTZ BRUCE H (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | LIPSHUTZ BRUCE H (US) | 2017-06-22 | — | — | US | disclosed |
| CN-101223130-A | Glutamate aggrecanase inhibitors | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-1049215-C | Process for preparing benzoquinazoline thymidylate synthase inhibitors | WELLOCOME FOUNDATION LTD (GB) | 2000-02-09 | — | — | CN | disclosed |
| US-5236927-A | Reduced toxicity; side effect reduction | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0204529-B1 | ANTI-CANCER QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| CN-1058208-A | PHARMACEUTICAL COMPOUNDS | WELLCOME FOUND (GB) | 1992-01-29 | — | — | CN | disclosed |
| EP-0204529-A2 | Anti-cancer quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | TPR, SOD1, ZNF207 | L3MBTL1 2264/4885KDM4E 1803/4885ALDH1A1 1764/4885 |
| US-11054430-B2 | Compounds and methods for the detection of methotrexate | MTX2, MTX1, DHFR | L3MBTL1 1953/4885KDM4E 3851/4885ALDH1A1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.